The US Food and Drug Administration may find that the flow and approval of new drug and biologic applications going forward are influenced by the Inflation Reduction Act’s timeline for when drugs become eligible for Medicare price negotiation, regulatory attorneys suggested during a 25 January Food and Drug Law Institute webinar.
Sponsors could time application submissions and push to get approvals in early February in order to maximize their products’ time on the market without price controls, they said. Under the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?